All In Biotech

Drug Trial Radar · NCT04706923

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

Aug 16, 2021

Primary completion

May 15, 2025

Study completion May 15, 2025

Sponsor

Lead sponsor
SymBio PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV

Conditions

  • Adenovirus Infections
  • Cytomegalovirus Infection

Interventions

  • BCVDrug

    Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety will be evaluated based on incidence and severity of Adverse Events, Serious Adverse Events and laboratory assessments.Time frame: From initiation of BCV administration up to 19 weeks
  2. Antiviral EffectsTime frame: From initiation of BCV administration up to 9 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    San Francisco, California

  • Research Site

    Chicago, Illinois

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Research Site

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Research Site

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Research Site

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.